These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 15973181

  • 1. Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil.
    Mannami M, Mitsuhata N.
    Transplantation; 2005 Jun 27; 79(12):1756-8. PubMed ID: 15973181
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
    Sugiyama K, Hyodo Y, Aikawa A.
    Int J Urol; 2015 Oct 27; 22(10):931-6. PubMed ID: 26108258
    [Abstract] [Full Text] [Related]

  • 3. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid.
    Tanabe K, Tokumoto T, Ishida H, Ishikawa N, Miyamoto N, Kondo T, Shimmura H, Setoguchi K, Toma H.
    Transplant Proc; 2004 Sep 27; 36(7):2175-7. PubMed ID: 15518791
    [Abstract] [Full Text] [Related]

  • 4. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J, Machida Y, Iwai T, Kuwabara N, Kabei K, Naganuma T, Kumada N, Kawashima H, Nakatani T.
    Clin Transplant; 2014 Jan 27; 28(1):80-7. PubMed ID: 24329776
    [Abstract] [Full Text] [Related]

  • 5. Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report.
    Nishimura H, Yamada Y, Hisano S, Mitsuke A, Tatarano S, Gotanda T, Hayami H, Nakagawa M, Enokida H.
    BMC Nephrol; 2018 Oct 05; 19(1):254. PubMed ID: 30290778
    [Abstract] [Full Text] [Related]

  • 6. Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplantation across the abo blood barrier: ELISA to detect humoral activity.
    Ishida H, Tanabe K, Furusawa M, Ishizuka T, Shimmura H, Tokumoto T, Hayashi T, Toma H.
    Transplantation; 2002 Oct 27; 74(8):1187-9. PubMed ID: 12438969
    [Abstract] [Full Text] [Related]

  • 7. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
    Yoshimura N, Ushigome H, Matsuyama M, Nobori S, Suzuki T, Sakai K, Okajima H, Okamoto M.
    Transplant Proc; 2012 Jan 27; 44(1):140-3. PubMed ID: 22310599
    [Abstract] [Full Text] [Related]

  • 8. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy.
    Saito K, Nakagawa Y, Suwa M, Kumagai N, Tanikawa T, Nishiyama T, Ueno M, Gejyo F, Nishi S, Takahashi K.
    Xenotransplantation; 2006 Mar 27; 13(2):111-7. PubMed ID: 16623803
    [Abstract] [Full Text] [Related]

  • 9. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors.
    Gloor JM, Lager DJ, Moore SB, Pineda AA, Fidler ME, Larson TS, Grande JP, Schwab TR, Griffin MD, Prieto M, Nyberg SL, Velosa JA, Textor SC, Platt JL, Stegall MD.
    Transplantation; 2003 Apr 15; 75(7):971-7. PubMed ID: 12698082
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
    Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T.
    Contrib Nephrol; 2009 Apr 15; 162():61-74. PubMed ID: 19001814
    [Abstract] [Full Text] [Related]

  • 11. ABO-incompatible kidney transplantation: first cases in Turkey.
    Tuncer M, Yücetin L, Tekin S, Demirbas A.
    Transplant Proc; 2012 Apr 15; 44(6):1703-5. PubMed ID: 22841248
    [Abstract] [Full Text] [Related]

  • 12. Transplantation of ABO-incompatible and living unrelated donor-recipient combinations.
    Ishikawa N, Yagisawa T, Sakuma Y, Fujiwara T, Nukui A, Yashi M, Miyamoto N.
    Transplant Proc; 2008 Sep 15; 40(7):2292-3. PubMed ID: 18790215
    [Abstract] [Full Text] [Related]

  • 13. Findings of graft biopsy specimens within 90 days after ABO blood group incompatible living donor kidney transplantation compared with ABO-identical and non-identical transplantation.
    Ushigome H, Okamoto M, Koshino K, Nobori S, Okajima H, Masuzawa N, Urasaki K, Yoshimura N.
    Clin Transplant; 2010 Jul 15; 24 Suppl 22():16-21. PubMed ID: 20590688
    [Abstract] [Full Text] [Related]

  • 14. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW.
    Transplantation; 1995 Aug 15; 60(3):225-32. PubMed ID: 7645033
    [Abstract] [Full Text] [Related]

  • 15. Analysis of the prevalence of systemic de novo thrombotic microangiopathy after ABO-incompatible kidney transplantation and the associated risk factors.
    Tasaki M, Saito K, Nakagawa Y, Imai N, Ito Y, Yoshida Y, Ikeda M, Ishikawa S, Narita I, Takahashi K, Tomita Y.
    Int J Urol; 2019 Dec 15; 26(12):1128-1137. PubMed ID: 31587389
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Improved graft survival in ABO-incompatible living donor kidney transplantation.
    Kaihara S, Okamoto M, Akioka K, Ogino S, Higuchi A, Kadotani Y, Nobori S, Yoshimura N.
    Transplant Proc; 2005 May 15; 37(4):1804-5. PubMed ID: 15919472
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
    Kabei K, Uchida J, Iwai T, Yamasaki T, Kuwabara N, Naganuma T, Kumada N, Nakatani T.
    Transpl Immunol; 2014 Aug 15; 31(2):92-7. PubMed ID: 24932811
    [Abstract] [Full Text] [Related]

  • 20. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
    Takahashi K, Saito K, Takahara S, Fuchinoue S, Yagisawa T, Aikawa A, Watarai Y, Yoshimura N, Tanabe K, Morozumi K, Shimazu M, IDEC-C2B8 ABO-I KTx Study Group.
    Clin Exp Nephrol; 2017 Aug 15; 21(4):705-713. PubMed ID: 27534951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.